AREF white papers address the need to educate members of Congress, the Administration, federal agencies, advocacy groups and public on important retirement issues.
AREF does research into government documents, Congressional and independent studies and media reports to validate its proposals.
- Time to End Taxpayer Rebates to Private Health Insurance Industry
- Reduce Price of Prescription Drugs
- Competitive Bidding on Prescription Drugs
- Prescription Drug Costs Internationally
- The Case for Legalizing Importation of Prescription Drugs from Canada
- Pre-Existing Conditions and Medigap / Medicare Advantage Policies
- Retiree Health Maintenance of Cost Protection (MCP)
- Health Care Access for Older Adults – Medicare Buy-In Option
- Medicare Out of Pocket Health Cost Limits
- Protecting Medicare and Trimming the Deficit
- NIH Should Use Its Authority to Mitigate Drugs Costs
- Testimonies on the High Cost of Prescription Drugs Bill 2015-2017
I have updated the NRLN’s white paper for 2021. The title is: It is time to end taxpayer subsidies to the private healthcare insurance industry for Medicare Advantage (MA) plans.
The NRLN supports competition from private healthcare plans and understands the financial challenges ahead for Medicare and the federal budget. However, we do not support bonus and rebate subsidies, or anti-competitive restrictions placed on the original Medicare Fee-for-Service (FFS) just to preserve the notion that private insurance plans may be more cost effective or provide better care than FFS, when the record shows they are not.